ERCC5 (XPG) is a key component of the nucleotide excision DNA repair pathway. In two recent case-control studies, we determined that ERCC5 transcript expression pattern in grossly normal human bronchial epithelial cells (NBEC) was different in individuals diagnosed with lung cancer compared with non-lung cancer controls. In this study, we tested the hypothesis that variation at cis-acting sites contributed to observed variation in ERCC5 transcript expression in NBEC. Allele-specific expression (ASE) was measured at transcribed polymorphic site rs1047768 in exon 2 of ERCC5 in NBEC complementary DNA (cDNA) of 22 individuals using allele-specific competitive polymerase chain reaction. ASE at rs1047768 was then assessed for association with allelotype at polymorphic sites rs751402 (E2F1 and YY1 recognition and response site) and rs2296147 (putative P53 recognition site) in the proximal promoter and 5# untranslated region, respectively, of ERCC5. Interindividual variation in recombination between rs751402, rs2296147 and rs1047768 in poly-heterozygotes was controlled for by allele-specific sequencing. Measured rs1047768 T:C allelic ratio was (i) significantly higher in NBEC cDNA compared with genomic DNA controls (P < 0.001) among samples heterozygous at both rs751402 and rs2296147; (ii) less high (P 5 0.02) for samples homozygous at rs751402 but heterozygous at rs2296147 and (iii) not significantly different (P 5 0.18) for doubly homozygous individuals. Here, we demonstrate that rs751402 A allele and rs2296147 T allele are associated with higher ASE of ERCC5 T allele transcript at rs1047768 in NBEC.
ERCC5 (XPG) is a key component of the nucleotide excision DNA repair pathway. In two recent case-control studies, we determined that ERCC5 transcript expression pattern in grossly normal human bronchial epithelial cells (NBEC) was different in individuals diagnosed with lung cancer compared with non-lung cancer controls. In this study, we tested the hypothesis that variation at cis-acting sites contributed to observed variation in ERCC5 transcript expression in NBEC. Allele-specific expression (ASE) was measured at transcribed polymorphic site rs1047768 in exon 2 of ERCC5 in NBEC complementary DNA (cDNA) of 22 individuals using allele-specific competitive polymerase chain reaction. ASE at rs1047768 was then assessed for association with allelotype at polymorphic sites rs751402 (E2F1 and YY1 recognition and response site) and rs2296147 (putative P53 recognition site) in the proximal promoter and 5# untranslated region, respectively, of ERCC5. Interindividual variation in recombination between rs751402, rs2296147 and rs1047768 in poly-heterozygotes was controlled for by allele-specific sequencing. Measured
Introduction
In previous studies, we identified a set of key DNA repair, antioxidant and transcription factor genes that exhibited significant intergene transcript expression correlation in normal human bronchial epithelial cells (NBEC) among individuals without lung cancer diagnosis (1) . Conversely, in NBEC of individuals diagnosed with lung cancer, intergene expression correlation was not observed. This difference between lung cancer cases and matched controls led to identification of a 14-gene transcript expression-based Lung Cancer Risk Test (LCRT). More recently, two case-control studies supported the association between the LCRT and prevalence of lung cancer (2) . Although this expression-based test has great potential value for identifying individuals at greatest risk for lung cancer, it requires bronchoscopy in order to obtain the NBEC samples for testing. Development of a less invasive DNA-based test from buccal swab or peripheral blood samples will require identification and mechanistic understanding of any underlying genetic variation responsible for interindividual variation in expression of genes comprised by the LCRT.
Excision repair cross-complementing rodent repair deficiency complementation group 5 (ERCC5), also known as Xeroderma Pigmentosum complementation group G (3), is one of the genes comprised by the LCRT (2) . We initially chose to investigate the genetic basis for interindividual variation in ERCC5 transcript levels for several reasons. First, in our prior studies, ERCC5 displayed the greatest difference between lung cancer cases and controls with respect to intergene transcript expression correlation in NBEC (1) . Further, it is a key component of the nucleotide excision repair pathway (4) . More recently, ERCC5 has also been shown to play a role in the regulation of transcription (5) (6) (7) (8) . Moreover, despite the important role ERCC5 plays in DNA repair, relatively little is known regarding its regulation or dysregulation at the transcript level or whether genetic variation influences its regulation.
Altered ERCC5 transcript expression is correlated with altered transcription domain-associated repair capacity (9, 10) , and experimental reduction of ERCC5 transcript levels decreases function of certain nucleotide excision repair-associated pathways (9) . Moreover, a number of studies report that variation in ERCC5 transcript and protein levels is associated with important phenotypic effects including interindividual variation in prevalence for several types of cancer (1, 11, 12) , as well as intertumor variation in responsiveness to radio-and platinum-based treatment (13) (14) (15) (16) . In our initial studies of ERCC5 transcript regulation, we determined that CEBPG and E2F1 are key ERCC5 trans-acting factors (17) . Based on these findings, it is probable that interindividual variation in transactivation by CEBPG and/or E2F1 contributes to interindividual variation in ERCC5 transcript expression, which, in turn, may contribute to variation in lung cancer risk (2) .
Recently, a common polymorphism in exon 2 of ERCC5 (refSNP ID j rs1047768; C / T; His46His) was associated with altered prevalence of lung cancer (18) . Additional studies corroborated this finding, reporting that loss of heterozygosity at rs1047768 polymorphic site, or nearby polymorphic cis-sites, was associated with prevalence for several other types of cancer (19) (20) (21) , as well as intertumor variation in responsiveness to radio-and platinum-based treatment (15, (22) (23) (24) . However, it is not yet known whether polymorphic site rs1047768, or nearby polymorphic cis-sites, has a significant effect on regulation of ERCC5 transcript levels (25) . Importantly, there are two common heritable polymorphisms in the proximal promoter region of ERCC5, one of which is an E2F1/YY1-binding and response site (rs751402) near the NCBI reference sequence transcript start site for ERCC5 (17) , and the other is a putative P53 consensus site (rs2296147) in the 5# untranslated region (UTR) (26) . In this study, we hypothesized that variation in ERCC5 transcript expression patterns in NBEC may in part be explained by heritable differences at one or both of these sites. To test this hypothesis, we developed allele-specific competitive polymerase chain reaction (PCR) reagents to measure allele-specific expression (ASE) at transcribed polymorphic site rs1047768 in exon 2 of ERCC5 in NBEC of 22 individuals. We then assessed ASE for association with allelotype at polymorphic sites rs751402 and rs2296147.
In recent haplotype mapping efforts, the region containing the ERCC5 proximal promoter and 5# UTR was determined to have a relatively high genomic recombination rate (27) . If one were to assume that the same alleles at adjacent polymorphic sites are always syntenic in poly-heterozygous individuals, this could introduce false-positive or -negative associations with ASE measurements. In this study, we controlled for interindividual variation in recombination by directly assessing the syntenic relationships among alleles at polymorphic sites rs751402, rs2296147 and rs1047768 with allele-specific sequencing and allelotyping (28) . Using this approach, we were able to directly measure association between putative regulatory alleles of interest and ASE of ERCC5 transcript in NBEC.
Materials and methods

Samples
Patients were recruited at the University of Toledo Medical Center according to a protocol approved by the University of Toledo Medical Center institutional review board. Inclusion criteria were willingness and ability to give informed consent, scheduled for diagnostic bronchoscopy and ages between 18 and 90. Exclusion criteria for this study were HIV, Hepatitis B or C or tuberculosis infection or medical instability. Pregnant women and prisoners were also excluded. For each participating subject, a normal bronchial epithelial cell (NBEC) sample was obtained by three to five cytology brush biopsies of grossly normal bronchial epithelium according to methods described previously (1). For lung cancer patients, sampling of NBEC was performed in the lung not involved with cancer. There were no patient adverse events resulting from collecting NBEC. Biographical characteristics of the 22 individuals used in this study are presented in supplementary Table I , available at Carcinogenesis Online.
Design of allele-specific competitive template internal standards A competitive template internal standard was prepared for each allele at the rs1047768 polymorphic site in ERCC5 gene according to methods described previously ( Figure 1A and B) (1, 17, 29) . Each internal standard was also designed with (i) a small internal sequence deletion to allow for electrophoretic size separation between co-amplified native template and synthetic allelespecific internal standard ( Figure 1B ) and (ii) the same forward and reverse priming sites as the corresponding native template sequence to ensure that native template and competitive template would amplify with the same efficiency using the same primers (30) . Thus, the only difference between the competitive templates for each allele was (i) the sequence at the 3#-terminus of the primer that directly overlies the polymorphic site of interest and (ii) a small internal deletion allowing for electrophoretic size separation between each competitive template ( Figure 1B ). Newly synthesized allele-specific internal standards were individually quantified on an Agilent 2100 Bioanalyzer using DNA Chips with DNA 1000 Kit reagents for visualization according to manufacturer's protocol (Agilent Technologies Deutschland GmbH, Waldbronn, Germany). Quantified internal standards were then combined in a known stoichiometric molar ratio (1:1) to create a stock concentrated standardized mixture of internal standards. This mixture of allele-specific internal standards was serially diluted to working concentrations (30) and then used in all subsequent experiments as a reference mixture of standards for quantifying numerical and/or relative allelic levels in native DNA samples ( Figure 1C ).
Controls in allele-specific competitive PCR Measurement of transcript expression for each gene relative to a known number of internal standard molecules within a standardized mixture of internal standards controls for all known sources of variation during PCR, including intersample variation in substances that interfere with the PCR reaction ( Figure 1C ) and generates data that are directly comparable across multiple experiments and institutions (31) . PCR inhibitors can be gene specific and may be allele specific as well. This method ensures no false negatives; if the PCR Figure 4 ) and reverse primer (exon 2 R in Figure 4 ). The same primers were used for amplification of native template and internal standard templates. The internal deletions in C allele and T allele internal standards were generated through PCR using reagents presented in supplementary Table II, available at Carcinogenesis Online. (C) Experimental design used to measure the abundance of each allele present in a native template DNA sample relative to a known number of allele-specific internal standard DNA template molecules. A known number of allele-specific internal standard molecules in a mixture at a known stoichiometric ratio are combined with a native template DNA sample in a master mixture of deoxyribonucleotide triphosphates, buffers and Taq polymerase. Sub-aliquots are then made into two tubes with allele-specific forward (exon 2 FT4 or FC4 in Figure 4 ) and reverse primers (exon 2 R in Figure 4 ). (D) Representative electropherograms of PCR reaction products from experiment in panel C. Top row of electropherograms: C allele specific primers (exon 2 FC4 with exon 2 R) and internal standard. Bottom row: T allele specific primers (exon 2 FT4 with exon 2 R) and internal standard. Numbers below electropherogram peaks are in units of base pairs. Amplicon sizes: T and C allele native amplicons each 128 bp, T allele internal standard amplicon 97 bp and C allele internal standard amplicon 116 bp.
Allele-specific expression of ERCC5 transcript in normal human bronchial epithelium fails, the internal standard product is not observed and there are no data to report. False positives are eliminated through use of a control PCR reaction with no native allele present ( Figure 1D i) and water only control.
Measurement of allele-specific ERCC5 expression
Genomic DNA (gDNA) was extracted from whole blood and/or NBEC as described previously (1, 17) . Total RNA was extracted from NBEC using TriReagent and reverse transcribed using M-MLV reverse transcriptase and oligo-dT primers as described previously (1) . In order to maximize information obtainable from the very small NBEC cDNA samples, a non-allele-specific primer pair was used to pre-amplify the region used for allele-specific measurement of ERCC5 exon 2 (Figures 1 and 4 ; supplementary Figure 1 and supplementary Table II are available at Carcinogenesis Online). ERCC5 transcript abundance in terms of transcript copy number per microliter cDNA was determined previously for each of the samples used in this study (1) . Based on these results, it was possible to determine the volume of each cDNA sample necessary to ensure that at least 1000 copies of transcript was loaded in each pre-amplification reaction. Loading at least 1000 copies of cDNA transcript in the reaction eliminated effect of stochastic sampling variation (29) . The presence of genomic material in NBEC cDNA before pre-amplification was quantified by measuring the number of genomic copies relative to number of ERCC5 cDNA molecules using commercially available SCGB1A1 genomic DNA reagents (Gene Express, Wilmington, NC). No significant genomic material was detected (,1%) in all but two samples (sample 303 and 649). For NBEC, cDNA samples 303 and 649, the systematic variation introduced by genomic material was not higher than analytical variation and thus determined not to significantly alter measured allele-specific expression ratios reported in Table II . Following pre-amplification, exon 2 amplicons were quantified by Fig. 2 . Titration of allele-specific internal standards with constant concentration of heterozygous gDNA native template (heterozygous T/C; rs1047768). (A) Experimental design to test signal response as allele-specific internal standards created for polymorphic site rs1047768 are titrated against a constant amount of heterozygous gDNA. The two allele-specific internal standards (T/C) were combined into a 1:1 stoichiometric relationship and then serially diluted. The number of internal standard molecules in each tube is shown. Equal volumes of a master mixture containing native template DNA, deoxyribonucleotide triphosphates, buffers and Taq polymerase were pipetted into each concentration of internal standards. Each dilution then was subdivided into two tubes, each containing reverse primer exon 2 R ( Figure 4 ) and one or the other of two allele-specific forward primers, exon 2 FT4 or FC4 ( Figure 4 ). (B) Representative electropherograms of PCR reaction products from experiment in panel A. Amplicon sizes: T and C allele native amplicons each 128 bp, T allele internal standard amplicon 97 bp and C allele internal standard amplicon 116 bp. (C) Plot of the ratio of native template to internal standard peak area versus number of internal standard molecules loaded for those electropherograms (from B) that were within a 1:10 to 10:1 ratio of peak areas. Based on prior experience, peak area ratios greater or less than a 10-fold difference have significantly increased analytical variation. A representative plot is shown of those measurements within a 1:10 to 10:1 ratio of peak areas. Closed squares, T allele PCR product; open circles, C allele PCR product.
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densitometry using an Agilent 2100 Bioanalyzer and subsequently diluted to 10 À14 M concentration. Allele-specific competitive PCR was then performed by combining a 1 ll aliquot of pre-amplified exon 2 from either cDNA or gDNA with a 1 ll aliquot of 10 À14 M standardized mixture of allele-specific internal standards in parallel PCR reactions with a primer set specific to each allele ( Figure 1C ). After allele-specific amplification, products were electrophoretically separated and quantified on an Agilent 2100 Bioanalyzer. Each ERCC5 allele was measured in triplicate from a single pre-amplification of each cDNA or gDNA sample (Table II; supplementary Table I is available at Carcinogenesis Online). Sequence information and positioning for preamplification and allele-specific primers is reported in Figure 4 ; supplementary Figure 1 and supplementary Table II are available at Carcinogenesis Online.
Genotyping and allele-specific sequencing and allelotyping Traditional sequencing and genotyping data were obtained using methods described previously (17) . In contrast, direct assessment of the syntenic relationship of alleles in gDNA from poly-heterozygous individuals was assessed in two steps using a modification of methods described previously (28) . First, reverse primer specific for C-allele at polymorphic site rs2296147 designed for allelespecific amplification (exon 1 RC w/RTX in Figure 4 ) was coupled with a common forward primer upstream of polymorphic site rs751402 (promoter F in Figure 4 ). PCR amplification products from each gDNA sample using this primer set were then sequenced (Integrated DNA Technologies, Coralville, IA) to identify syntenic alleles at rs751402 and rs2296147. If C allele at rs2296147 was found to be syntenic with G allele at rs751402, T allele at rs2296147 was assumed to be syntenic with A allele at rs751402. Next, a set of forward primers designed for allele-specific amplification of each allele at polymorphic site rs2296147 (exon 1 FT and FC in Figure 4 ) were coupled with a common reverse primer downstream of polymorphic site rs1047768 (exon 2 R in Figure 4 ). PCR amplification product from NBEC cDNA using these primer sets was then allelotyped to identify syntenic alleles at rs2296147 and rs1047768 using allelespecific competitive PCR reagents outlined in Figures 1 and 2 . cDNA instead of gDNA was used in step two in order to avoid the need to PCR amplify across $5 kbp of intron 1 gDNA. Primers used for allele-specific sequencing and allelotyping are reported in Figure 4 ; supplementary Figure 1 and supplementary Table II are available at Carcinogenesis Online. Electropherograms for both traditional and allele-specific sequencing, as well as allele-specific allelotyping on Agilent 2100, are available upon request.
Statistical analysis
Bartlett's test for homogeneity of variances was used to assess significance of difference in coefficient of variation between allele-specific expression measurements performed in all gDNA and cDNA (32). Fisher's distribution test (F-test) was used to assess intergroup differences in variation in allele-specific ERCC5 transcript expression in cDNA samples grouped by genotype compared with allele-specific ERCC5 products from matched gDNA samples. Homoscedastic and heteroscedastic Student's t-test, depending on F-test significance threshold of 0.05, was performed to assess significance of difference in central tendency of allele-specific expression measurement between cDNA grouped by genotype and gDNA controls (P-values reported in Figure 3 ).
Results
Sample genotyping and biographical characteristics
Of the enrolled subjects included in this study, genotyping data were obtained for 81 individuals at polymorphic sites rs751402, rs2296147 and rs1047768 (Table I) . From these 81 individuals, 28 were identified as heterozygous for T and C alleles at rs1047768, and of these samples, 22 provided sufficient NBEC cDNA for analysis. Among these 22 rs1047768-heterozygous individuals, seven were heterozygous at both rs751402 and rs2296147, nine were homozygous at rs751402 and heterozygous at rs2296147, none were heterozygous at rs751402 and homozygous at rs2296147, and six were homozygous at both rs751402 and rs2296147. Genotyping data and biographical characteristics of the 22 individuals used in this study are presented in Table II; supplementary Table I , available at Carcinogenesis Online.
Performance testing of allele-specific competitive PCR reagents Four allele-specific primer sets were designed for each allele at the reporter polymorphic site (rs1047768), each with 3# mismatch over the polymorphic site and three of four that contained one of three possible mismatches at the 3# penultimate base (Figure 1A and B; supplementary Figure 1 and supplementary Table II are available at Carcinogenesis Online) (33) . All four primer sets for each allele were assessed for allelic specificity in parallel PCR reactions with homozygous, heterozygous or no native template DNA controls in the presence of allele-specific internal standards ( Figure 1C and D) . Of the four primers sets tested for each allele, only the primer sets combining exon 2 R primer with either exon 2 FT4 primer (T allele primer) or exon 2 FC4 primer (C allele primer) met performance criteria (supplementary Figure 1 and Figure 1 . The threshold acceptable performance criterion for allele-specific primers was set as ,5% nontargeted allele detected in amplification product from a sample homozygous for the non-targeted allele ( Figure 1D ii and iii). Actual copy number of native template loaded was quantified using traditional competitive PCR procedures (30) . A 5% specificity threshold for each allele is analogous to a lower and upper limit of allelic ratio measurement of 1:20 and 20:1, respectively, enabling reliable measurement of a 400-fold range in allelic ratio. Amplification of a PCR master mixture containing internal standard but no native template with either T or C allele primer sets resulted in only allele-specific internal standard peak corresponding to the allele-specific primer set used ( Figure 1D i) . Amplification of a PCR mixture containing homozygous T (rs1047768) gDNA and internal standard templates with either T or C allele primer sets resulted in a peak for C allele-specific internal standard when allele C-specific primers was included and Fig. 3 . Measurement of ERCC5 transcript rs1047768 T:C allelic ratio in normal bronchial epithelium. Summary results from allele-specific competitive PCR measurement of ERCC5 allelic ratio at polymorphic site rs1047768 in NBEC gDNA (closed triangles) and matched cDNA (gray symbols) for 22 individuals. Table below scatterplot indicates genotype of samples plotted above. For gDNA, the group of samples comprising all allelotypes at polymorphic sites rs751402 and rs2296147 were compared together. For cDNA, groups of samples with varying genotypes at polymorphic sites rs751402 and rs2296147 were compared separately (results for individual samples in Table II ). y Represents sample 298 and represents sample 675. Bracketing and P-values are reported for Student's t-test with sample 298 y excluded from analysis.
Allele-specific expression of ERCC5 transcript in normal human bronchial epithelium both allele-specific native and internal standard when T allele primers was in the PCR reaction ( Figure 1D ii). Homozygous C (rs1047768) gDNA and internal standard templates with either T or C allele primer sets resulted in only allele-specific internal standard for T allele PCR reaction, and both native and allele-specific internal standard present for C allele PCR reaction ( Figure 1D iii). Heterozygous T/C (rs1047768) gDNA and internal standard templates with either T or C allele primer sets resulted in both native and allele-specific internal standard present for T and C allele PCR reactions ( Figure 1D iv). Performance observations for each primer set tested are annotated in supplementary Table II , available at Carcinogenesis Online. Competitive PCR is capable of accurately and precisely measuring DNA template copy numbers that vary over a range .10 orders of magnitude (29) (E.L.Crawford and J.C.Willey, unpublished results). However, for the purposes of measuring allele-specific expression ratios, it is possible to limit the range of measurement to a relatively narrow range of absolute copy number. This is because the key parameter being measured is the relative amount of allele from the two homologous chromosomes. Thus, whether the amount of DNA (gDNA or cDNA) from 1 cell or 10 million cells is included in the PCR reaction the relative amount from each of the two alleles will be the same. Consequently, the parameters to consider when deciding how much nucleic acid to include in the PCR reaction are (i) what is the minimum that must be present to avoid analytical variation due to stochastic sampling error and (ii) what is the maximum amount that should be used to avoid unnecessary waste of sample. Based on these considerations, we typically include cDNA or gDNA representing 10 2 -10 4 copies. Another consideration is the range over which measurement of one allele to another is linear. The range over which this can be tested is limited by the allelic specificity of the primers (typically .95% for this study or a 1:20 ratio of non-specific to specific) enabling measurement of a 400-fold range of one allele to the other (i.e. allele A/B ratio from 1:20 to 20:1). Moreover, variation in allelespecific expression ratio from autosomal genes typically varies ,10-fold. To assess linearity of signal response, we decided to titrate allele-specific internal standards over a range of 60-12 000 molecules in the presence of a constant amount of heterozygous gDNA template (1000 genome copies) (Figure 2 ). The acceptable threshold performance criterion for each allele was a signal-to-analyte response associated with an R 2 !0.95 in triplicate ( Figure 2C ). Importantly, each allele exhibited a nearly identical slope of signal-to-analyte response ( Figure 2C ).
Allele-specific expression measurement of ERCC5 transcript in NBEC samples ERCC5 allele-specific transcript expression was measured in NBEC cDNA samples from 22 individuals heterozygous at the rs1047768 reporter polymorphic site and with varying allelotype at the putative regulatory polymorphic sites rs2296147 and rs751402 (Table II and Figure 3) . As a control, allele-specific ERCC5 levels were measured in gDNA samples from the same 22 individuals. Among the 22 samples assessed, there was no significant difference (P 5 0.18) in analytical variation for replicate measurement of cDNA samples (average analytical CV 5 10.8%) compared with gDNA samples (average analytical CV 5 11.5%). In contrast, there was significantly higher (P , 0.001) intersample variation in allelic ratio measured at polymorphic site rs1047768 for the group of 22 NBEC cDNA (average biological CV 5 23.7%) compared with corresponding gDNA controls (average biological CV 5 10.1%). Moreover, for each gDNA sample assessed, the T and C alleles at rs1047768 were in a 1:1 relationship indicating absence of copy number variation. Among all 22 NBEC cDNA assessed, there was a significant (P 5 0.003) 22% higher average T:C allelic ratio at polymorphic site rs1047768 relative to corresponding gDNA controls. The higher T:C ratio was predominantly observed among NBEC cDNA samples heterozygous at both rs751402 and rs2296147 and with synteny between A allele at rs751402, T allele at rs2296147 and T allele at rs1047768. This haplotype was associated with a 34% higher T:C allelic ratio compared with gDNA controls (P , 0.01). When an outlier was removed from analysis, for reasons discussed below (sample 298; single dagger in Figure 3 and Table II,  notes in Table I ), the mean difference in measured T:C ratio increased to 44% (P , 0.001). For individuals homozygous at rs751402 but heterozygous at rs2296147, the increase in T:C allelic ratio (31%) relative to gDNA was lower but still significant (P 5 0.02). NBEC cDNA samples from individuals doubly homozygous for polymorphic sites rs751402 and rs2296147 displayed no significant difference in T:C allelic ratio (P 5 0.18) compared with gDNA controls.
Characterization of haplotype structures at ERCC5 promoter
For the 81 individuals enrolled in this study, the most common haplotype structures for polymorphic sites rs751402-rs2296147-rs1047768 were G-C-C (38%) and A-T-T (20%) ( Table I) . However, a variety of syntenic relationships were observed for the remaining 42% of chromosomes assessed, which is consistent with haplotype mapping data indicating that this region is a recombination hot spot (27) . From our haplotype frequency data, we estimate that 4.2% of triply heterozygous and 3.9-7.3% of doubly heterozygous individuals, or $1 in 20 poly-heterozygous individuals, exhibit deviation from the expected syntenic phase of alleles (Table I) . As described in Materials and Methods, a set of 22 individuals were identified that were heterozygous at the rs1047768 polymorphic site and had different genotypes at the cis-polymorphic sites with putative regulatory function, rs751402 and rs2296147. Allele-specific PCR pre-amplification with subsequent sequencing or allelotyping was then used to directly assess the syntenic relationship among alleles at each polymorphic site in each of the 16 poly-heterozygous individuals.
Among the 16 poly-heterozygous individuals assessed for ASE, one triply heterozygous individual (sample 675; double dagger in Figure 3 and Table II ) was identified with deviation from expected synteny among alleles at rs2296147 relative to those at rs751402 and rs1047768. More specifically, this individual exhibited additional haplotype structural features that probably resulted from processes more complex than germ line recombination. Through allele-specific sequencing of gDNA, we determined that C allele at polymorphic site rs751402  rs2296147  rs1047768  G  C  C  6 2  A  T  T  3 3  G  T  C  2 7  G  T  T  2 6  G  C  T  7  A  T  C  5  A  C  T Table II; supplementary Table I is available at Carcinogenesis Online.
T.M.Blomquist et al. Illustration of the eight primer pairs used in the allele-specific expression association study of ERCC5. The furthest upstream TSS in this schematic is the proposed NCBI mRNA refseq TSS for ERCC5 NM_000123.2. All positions noted are relative to this site. F, a forward primer (i.e. sense to the coding strand of ERCC5); R, a reverse primer (i.e. antisense to the coding strand). Promoter F primer, a non-allele-specific primer used in combination with exon 1 R for non-allele-specific sequencing of gDNA or in combination with exon 1 RC/RTX for allele-specific amplification from rs2296147 to determine synteny between alleles at rs2296147 and rs751402. Exon 1 F primer, a non-allele-specific primer used in combination with exon 2 R primer to pre-amplify cDNA for allele-specific studies. Exon 1 FT4 and exon 1 FC4, forward primers with both 3# ultimate and penultimate mismatches used in combination with exon 2 R for specific amplification from T allele or C allele, respectively, at rs2296147 to determine synteny between alleles at rs2296147 and rs1047768. Exon 2 FT4 and exon 2 FC4, forward primers with both 3# ultimate and penultimate mismatches used in combination with exon 2 R for specific amplification from T allele or C allele, respectively, at rs1047768. Exon 1 RC, a primer with only a 3# ultimate mismatch used in combination with promoter F primer for allele-specific amplification of rs2296147 C allele to determine synteny between alleles at rs2296147 and rs751402. TX 5 a primer with a 3#-amino modification that prevents extension of the T allele. When combined with exon 1 RC primer, exon 1 RTX primer improved specificity of rs2296147 C allele amplification by blocking exon 1 RC amplification of rs2296147 T allele. Annotation regarding usage of each of the eight primer pairs accompanies each pair. Further performance notes and sequence information for each of the primer pairs are provided in supplementary Figure 1 and supplementary Table II are available at Carcinogenesis Online.
Allele-specific expression of ERCC5 transcript in normal human bronchial epithelium rs2296147 was syntenic with both G and A alleles at rs751402. And by allele-specific allelotyping of NBEC cDNA, it was determined that T allele at rs2296147 was directly syntenic with both T and C alleles at rs1047768 (Table I) .
Variation in ERCC5 transcription start site As is commonly observed for genes with CpG-rich promoters (34) , the site of ERCC5 transcription initiation is highly variable and occurs over a range of .400 bp from nucleotide 102296159 to nucleotide 102296575 on chromosome 13 (35) . Notably, dense clusterings of transcription start site (TSS) are centered over genomic positions 102296192, 102296383 and 102296440, rather than position 102296175 as reported by NCBI for ERCC5 messenger RNA refseq NM_000123.2. We have confirmed that a similar graded TSS phenomenon is also operative in NBEC through direct transcript expression measurement using a nested primer approach (T.M.Blomquist, E.L.Crawford and J.C.Willey, unpublished results).
Effect of allelotype on variation in ERCC5 TSS
Preliminary studies point to a genetic variation, as yet undetermined, that affects the TSS distribution of ERCC5 in NBEC. Specifically, in this study, there was evidence for allele-specific variation in TSS in three samples. For example, in sample 675, using primers that bind to the 5# UTR, the abundance of transcripts derived from rs1047768 T allele was 3-fold greater than that for transcripts derived from the C allele. However, using primers that solely amplify exon 2, the T:C ratio was 1.62-fold ( Figure 3 and Table II; supplementary Table I is available at Carcinogenesis Online). Thus, in this sample, a TSS near the 5# end of the transcript was used more for the T allele compared with the C allele. In contrast, for sample 298, no transcripts derived from the parental chromosomes with T allele at rs1047768 used the TSS near the 5# end; they all lacked a 5# UTR. Thus, in this sample, transcripts with 5# UTR intact were derived only from the parental chromosome with C allele at rs1047768. Lack of 5# UTR from transcripts derived from the parental chromosome with T allele at rs1047768 was also observed in sample 338. There was no clear association between any of the polymorphic sites assessed in this study and variation in TSS. The results observed for these three samples may be the result of a complex overlap of haplotype structures, some of which were not studied.
Discussion
The data reported here are the first to directly associate specific variants at cis-acting polymorphic sites with differences in level of ERCC5 transcript expression. These data indicate that multiple cis-acting genetic variant sites, including rs751402, rs2296147 and possibly other sites, but less probably rs1047768, affect multiple biological aspects of ERCC5 transcript regulation in normal human bronchial epithelium, including ASE at exon 2 and possibly transcript start site usage. In this study, we measured ASE in ERCC5 using allele-specific competitive PCR and methods that enabled direct measurement of synteny between alleles at the marker site and alleles at adjacent cis-variant sites. This approach controlled for interindividual variation in genomic recombination in the ERCC5 promoter region.
As a result, we confirmed that the higher expression of T allele measured at rs1047768 was associated with syntenic alleles A at rs751402 and T at rs2296147. These results contribute to a mechanistic explanation for previous studies demonstrating that interindividual variation in ERCC5 transcript expression or polymorphic cis-sites is associated with cancer prevalence, radio-and platinum-based treatment response or DNA repair capacity (1, (9) (10) (11) (12) (13) (14) (15) (16) (18) (19) (20) (21) (22) (23) (24) . Allele-specific measurement of transcript expression is a powerful method for determining the effect of cis-polymorphic sites on transcript regulation (36, 37) . Other approaches for allele-specific transcript measurement have been described (36) , and many of these techniques rely upon the intrinsic quality control inherent in measuring relative allelic levels within a single reaction vessel (29,31,38,39) . However, despite this built-in quality control step, numerous sources of analytical variation potentially remain uncontrolled for by this approach alone, which may result in inaccurate and/or low precision of ASE measurement. In this study, we sought to implement additional quality control measures. Key to this effort was use of competitive PCR in allele-specific quantification. Properly designed competitive PCR offers highly reproducible measurement of DNA template copy numbers, with excellent linear dynamic range and target analyte specificity at a relatively low cost (29, 30) . Allelespecific competitive PCR combines competitive PCR with allelespecific PCR priming approaches (33) to precisely and accurately quantify alleles described previously (Figure 1) .
One additional source of experimental error in ASE association studies is variable genomic recombination between polymorphic sites in poly-heterozygous individuals (27) . In this study, ASE and allelotyping measurements were linked through a modification of methods described previously (28) (29) (30) 33) , enabling direct measurement of which allele at a putative cis-regulatory polymorphic site is syntenic with each allele at the polymorphic site used to measure ASE (Figure 4) . For sample 298, we hypothesized that reversal of the expected synteny was responsible for the significantly lowered ASE of ERCC5 compared with its genotype cohort group (Figure 3) (40) . However, our direct measurements showed that this not to be the case (Table I ). It is probable that the significant alteration of measured ASE ratio for sample 298 ( Figure 3 ) may be due, in part, to cis-acting genetic variation affecting TSS distribution not controlled for here (Table I; supplementary Table I is available at Carcinogenesis Online).
Recently, differential ASE of BRCA1 and BRCA2 in lymphocytes was associated with altered prevalence of Breast Cancer (41) , and ASE of TGFBR1 may be associated with altered predisposition to colon cancer in certain genetic backgrounds (42, 43) . These recent studies indicate that variation in ASE for genes with high prior likelihood of involvement in complex traits may be clinically relevant, and ASE in peripheral blood may be useful in the study and diagnosis of complex disease traits such as cancer risk. The design of ASE based measurements is particularly suited to clinical diagnostics because the numerator and denominator of ASE ratios are measured from the same exact gene, eliminating many sources of analytical error derived from variation in RNA extraction efficiency, reverse transcription efficiency and the need for house-keeping gene normalization (31) . ASE ratios also may serve as clinically relevant indicators of the functionality or activation of certain trans-acting regulatory pathways if haplotype structures are appropriately controlled for (44) .
It is possible that unknown and uncontrolled for trans-regulatory effects, acting through cis-polymorphic sites, may only exert their effect in certain contexts (45) . For example, polymorphic site rs2296147 is a putative P53 transcription factor-binding site based on in silico analysis (26) . It is reasonable to hypothesize that interindividual variation in genotoxic stress acting on this site may result in significant variation in ERCC5 ASE (45) . Moreover, polymorphic site rs751402 is a known E2F1 and YY1 transcription factor response and binding site based on in vitro experimentation (17) and increased bronchial epithelial cell cycling in some individuals, for example those with chronic bronchitis, may result in differential ASE pattern. Indeed, based on our preliminary observations in two bronchogenic carcinoma cell-line models, changes in allelic imbalance in ERCC5 transcript expression is observed throughout the cell cycle, with rs1047768 T allele transcript expression peaking in S-phase (T.M.Blomquist, E.L.Crawford and J.C.Willey, unpublished results). However, this phenomenon is not completely explained by allelotype at rs751402 or rs2296147 polymorphic sites and will require further investigation. Additional findings from this study suggest that cisacting genetic variation affecting ERCC5 transcript start site location may contribute to the broadly distributed transcript start site region observed in this study as well as studies from other laboratories (35) . This may have important effects in light of the recent report that 5# UTR length of ERCC5 is critical for its recruitment to the polyribosomal cellular fraction and increased translation in response to protein kinase C activity and DNA damage response (46) . Among the samples studied thus far, it does not appear that allelotype at rs751402, T.M. Blomquist et al. rs2296147 or rs1047768 is associated with changes in ASE measured in the 5# UTR of ERCC5 transcript in NBEC. However, this does not rule out a role for one or more of these polymorphic sites under certain trans-acting conditions (45) .
It is possible that genetic variation in distant enhancer sequences, as well as in transcribed portions of ERCC5 gene not investigated here (e.g. variant miRNA recognition motifs) (47) , may be important in the regulation of ERCC5 transcript levels. However, because the ERCC5 promoter region is a hot spot for recombination, we would expect that measured allele-specific expression ratios would be bidirectionally spread (40) if distant cis-acting sequence variations were responsible for influencing ERCC5 transcript levels. Still, we cannot rule out the possibility of indirect effect by a nearby cis-acting genetic variation in linkage disequilibrium with rs751402 and/or rs2296147.
In this study, we determined that cis-acting variation can influence ASE of ERCC5 as much as 2-fold (sample 715; Table II ). In recent studies, a 3-fold reduction in total ERCC5 transcript expression was sufficient to completely eliminate transcription-domain-associated repair activity under certain contexts (9) . Importantly, nucleotide excision repair activity is crucial for efficient repair of platinum-based DNA adducts. Recently, variation in rs751402 allelotype was associated with altered oxaliplatin response and progression free survival for advanced colorectal cancer patients (48) . Together, the findings from this study, in addition to numerous association studies, support the conclusion that variation in ERCC5 transcript expression caused by variation in ERCC5 cis-regulatory sites has important phenotypic consequences for DNA repair, cancer risk and treatment response.
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